Fortress Biotech, Inc. Research and Development Expense
Fortress Biotech, Inc. (FBIO) reported Research and Development Expense of $9.45 million for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2024-11-14
- Fortress Biotech, Inc. research and development expense for the quarter ending 2024-09-30 was $9.45M, a 53.58% decline year-over-year.
- Fortress Biotech, Inc. research and development expense for the quarter ending 2024-06-30 was $12.67M, a 60.58% decline year-over-year.
- Fortress Biotech, Inc. research and development expense for the quarter ending 2024-03-31 was $24.84M, a 37.13% decline year-over-year.
- Fortress Biotech, Inc. research and development expense for the quarter ending 2023-12-31 was $14.08M, a 59.92% decline year-over-year.
- Fortress Biotech, Inc. research and development expense for fiscal 2023 was $106.07M, a 21.36% decline from fiscal 2022.
- Fortress Biotech, Inc. research and development expense for fiscal 2022 was $134.88M, a 4.66% increase from fiscal 2021.
- Fortress Biotech, Inc. research and development expense for fiscal 2021 was $128.87M, a 101.01% increase from fiscal 2020.
- Fortress Biotech, Inc. research and development expense for fiscal 2020 was $64.11M, a 21.17% decline from fiscal 2019.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month | Research and Development Expense 12 month as first filed | Research and Development Expense 63 month | Research and Development Expense 66 month | Research and Development Expense 69 month | Research and Development Expense 72 month | Research and Development Expense 75 month | Research and Development Expense 78 month | Research and Development Expense 81 month | Research and Development Expense 84 month | Research and Development Expense 87 month | Research and Development Expense 90 month | Research and Development Expense 93 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | $9.45M 10-Q · filed 2024-11-14 | $22.12M derived: sum of 2 quarters · filed 2024-11-14 | $46.94M 10-Q · filed 2024-11-14 | $61.03M derived: sum of 4 quarters · filed 2024-11-14 | |||||||||||||
| 2024-06-30 | $12.67M 10-Q · filed 2024-08-13 | $37.49M 10-Q · filed 2024-08-13 | $51.59M derived: sum of 3 quarters · filed 2024-08-13 | $71.93M derived: sum of 4 quarters · filed 2024-11-14 | |||||||||||||
| 2024-03-31 | $24.84M 10-Q · filed 2024-05-15 | $38.91M derived: sum of 2 quarters · filed 2024-05-15 | $59.26M derived: sum of 3 quarters · filed 2024-11-14 | $91.41M derived: sum of 4 quarters · filed 2024-11-14 | |||||||||||||
| 2023-12-31 | $14.08M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $34.42M derived: sum of 2 quarters · filed 2024-11-14 | $66.57M derived: sum of 3 quarters · filed 2024-11-14 | $106.07M 10-K · filed 2024-03-28 | |||||||||||||
| 2023-09-30 | $20.35M 10-Q · filed 2024-11-14 | $52.49M derived: sum of 2 quarters · filed 2024-11-14 | $92.00M 10-Q · filed 2024-11-14 | $127.12M derived: sum of 4 quarters · filed 2024-11-14 | |||||||||||||
| 2023-06-30 | $32.14M 10-Q · filed 2024-08-13 | $71.65M 10-Q · filed 2024-08-13 | $106.77M derived: sum of 3 quarters · filed 2024-08-13 | $136.67M derived: sum of 4 quarters · filed 2024-08-13 | |||||||||||||
| 2023-03-31 | $39.51M 10-Q · filed 2024-05-15 | $74.63M derived: sum of 2 quarters · filed 2024-05-15 | $104.53M derived: sum of 3 quarters · filed 2024-05-15 | $137.66M derived: sum of 4 quarters · filed 2024-05-15 | |||||||||||||
| 2022-12-31 | $35.12M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $65.02M derived: sum of 2 quarters · filed 2024-03-28 | $98.15M derived: sum of 3 quarters · filed 2024-03-28 | $134.88M 10-K · filed 2024-03-28 | |||||||||||||
| 2022-09-30 | $29.90M 10-Q · filed 2023-11-14 | $63.03M derived: sum of 2 quarters · filed 2023-11-14 | $99.75M 10-Q · filed 2023-11-14 | $142.81M derived: sum of 4 quarters · filed 2023-11-14 | |||||||||||||
| 2022-06-30 | $33.13M 10-Q · filed 2023-08-14 | $69.85M 10-Q · filed 2023-08-14 | $112.91M derived: sum of 3 quarters · filed 2023-08-14 | $140.99M derived: sum of 4 quarters · filed 2023-08-14 | |||||||||||||
| 2022-03-31 | $36.72M 10-Q · filed 2023-05-15 | $79.78M derived: sum of 2 quarters · filed 2023-05-15 | $107.86M derived: sum of 3 quarters · filed 2023-05-15 | $141.69M derived: sum of 4 quarters · filed 2023-05-15 | |||||||||||||
| 2021-12-31 | $43.05M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $71.13M derived: sum of 2 quarters · filed 2023-03-31 | $104.97M derived: sum of 3 quarters · filed 2023-03-31 | $128.87M 10-K · filed 2023-03-31 | |||||||||||||
| 2021-09-30 | $28.08M 10-Q · filed 2022-11-14 | $61.91M derived: sum of 2 quarters · filed 2022-11-14 | $85.81M 10-Q · filed 2022-11-14 | $100.03M derived: sum of 4 quarters · filed 2022-11-14 | |||||||||||||
| 2021-06-30 | $33.83M 10-Q · filed 2022-08-11 | $53.99M 10-Q · filed 2022-08-11 | $71.95M derived: sum of 3 quarters · filed 2022-08-11 | $85.71M derived: sum of 4 quarters · filed 2022-08-11 | |||||||||||||
| 2021-03-31 | $20.15M 10-Q · filed 2022-05-12 | $38.12M derived: sum of 2 quarters · filed 2022-05-12 | $51.87M derived: sum of 3 quarters · filed 2022-05-12 | $69.15M derived: sum of 4 quarters · filed 2022-05-12 | |||||||||||||
| 2020-12-31 | $17.96M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $31.72M derived: sum of 2 quarters · filed 2022-03-28 | $48.99M derived: sum of 3 quarters · filed 2022-03-28 | $64.11M 10-K · filed 2022-03-28 | |||||||||||||
| 2020-09-30 | $13.76M 10-Q · filed 2021-11-15 | $31.03M derived: sum of 2 quarters · filed 2021-11-15 | $46.15M 10-Q · filed 2021-11-15 | ||||||||||||||
| 2020-06-30 | $17.27M 10-Q · filed 2021-08-16 | $32.39M 10-Q · filed 2021-08-16 | |||||||||||||||
| 2020-03-31 | $15.12M 10-Q · filed 2021-05-17 | ||||||||||||||||
| 2019-12-31 | $81.33M 10-K/A · filed 2021-04-09 | ||||||||||||||||
| 2019-03-31 | $23.27M 10-Q · filed 2019-05-10 | ||||||||||||||||
| 2018-12-31 | $87.38M 10-K · filed 2020-03-16 | $83.33M 10-K · filed 2019-03-18 | |||||||||||||||
| 2018-03-31 | $24.96M 10-Q · filed 2019-05-10 | $12.00K 10-Q · filed 2018-05-10 | |||||||||||||||
| 2017-12-31 | $48.32M 10-K · filed 2019-03-18 | $52.49M 10-K · filed 2018-03-16 | |||||||||||||||
| 2017-03-31 | $8.40M 10-Q · filed 2017-05-10 | $22.12M derived: sum of 2 quarters · filed 2018-03-16 | $29.44M derived: sum of 3 quarters · filed 2018-03-16 | $35.78M derived: sum of 4 quarters · filed 2018-03-16 | |||||||||||||
| 2016-12-31 | $13.72M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $21.03M derived: sum of 2 quarters · filed 2018-03-16 | $27.38M derived: sum of 3 quarters · filed 2018-03-16 | $35.13M 10-K · filed 2018-03-16 | -$35.13M 10-K · filed 2017-03-16 | ||||||||||||
| 2016-09-30 | $7.32M 10-Q · filed 2016-11-09 | $13.66M derived: sum of 2 quarters · filed 2016-11-09 | $21.42M 10-Q · filed 2016-11-09 | $38.04M derived: sum of 4 quarters · filed 2018-03-16 | |||||||||||||
| 2016-06-30 | $6.35M 10-Q · filed 2016-08-09 | $14.10M 10-Q · filed 2016-08-09 | $30.72M derived: sum of 3 quarters · filed 2018-03-16 | $39.79M derived: sum of 4 quarters · filed 2018-03-16 | |||||||||||||
| 2016-03-31 | $7.74M 10-Q · filed 2016-05-10 | $24.37M derived: sum of 2 quarters · filed 2018-03-16 | $33.45M derived: sum of 3 quarters · filed 2018-03-16 | $35.86M derived: sum of 4 quarters · filed 2018-03-16 | |||||||||||||
| 2015-12-31 | $16.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $25.71M derived: sum of 2 quarters · filed 2018-03-16 | $28.12M derived: sum of 3 quarters · filed 2018-03-16 | $29.81M 10-K · filed 2018-03-16 | $18.40M 10-K · filed 2016-03-15 | ||||||||||||
| 2015-09-30 | $9.07M 10-Q · filed 2016-11-09 | $11.48M derived: sum of 2 quarters · filed 2016-11-09 | $13.17M 10-Q · filed 2016-11-09 | $14.89M derived: sum of 4 quarters · filed 2016-11-09 | |||||||||||||
| 2015-06-30 | $2.41M 10-Q · filed 2016-08-09 | $4.07M 10-Q · filed 2016-08-09 | $5.82M derived: sum of 3 quarters · filed 2016-08-09 | $7.43M derived: sum of 4 quarters · filed 2016-08-09 | |||||||||||||
| 2015-03-31 | $1.64M 10-Q · filed 2016-05-10 | $3.41M derived: sum of 2 quarters · filed 2016-05-10 | $5.02M derived: sum of 3 quarters · filed 2016-05-10 | $7.39M derived: sum of 4 quarters · filed 2016-05-10 | |||||||||||||
| 2014-12-31 | $1.77M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $3.38M derived: sum of 2 quarters · filed 2016-03-15 | $5.75M derived: sum of 3 quarters · filed 2016-03-15 | $10.24M 10-K · filed 2016-03-15 | |||||||||||||
| 2014-09-30 | $1.61M 10-Q · filed 2015-11-09 | $3.99M derived: sum of 2 quarters · filed 2015-11-09 | $8.47M 10-Q · filed 2015-11-09 | $15.03M derived: sum of 4 quarters · filed 2016-03-15 | |||||||||||||
| 2014-06-30 | $2.38M 10-Q · filed 2015-08-10 | $6.87M 10-Q · filed 2015-08-10 | $13.42M derived: sum of 3 quarters · filed 2016-03-15 | $18.78M derived: sum of 4 quarters · filed 2016-03-15 | |||||||||||||
| 2014-03-31 | $4.49M 10-Q · filed 2015-05-11 | $11.04M derived: sum of 2 quarters · filed 2016-03-15 | $16.40M derived: sum of 3 quarters · filed 2016-03-15 | $24.20M derived: sum of 4 quarters · filed 2016-03-15 | $72.18M 10-Q · filed 2014-05-12 | ||||||||||||
| 2013-12-31 | $6.55M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $11.91M derived: sum of 2 quarters · filed 2016-03-15 | $19.71M derived: sum of 3 quarters · filed 2016-03-15 | $25.68M 10-K · filed 2016-03-15 | $67.69M 10-K · filed 2014-03-14 | ||||||||||||
| 2013-09-30 | $5.36M 10-Q · filed 2014-11-06 | $13.16M derived: sum of 2 quarters · filed 2014-11-06 | $19.13M 10-Q · filed 2014-11-06 | $23.70M derived: sum of 4 quarters · filed 2015-03-16 | $61.14M 10-Q · filed 2013-11-01 | ||||||||||||
| 2013-06-30 | $7.79M 10-Q · filed 2014-08-11 | $13.77M 10-Q · filed 2014-08-11 | $18.34M derived: sum of 3 quarters · filed 2015-03-16 | $22.12M derived: sum of 4 quarters · filed 2015-03-16 | $55.78M 10-Q · filed 2013-08-05 | ||||||||||||
| 2013-03-31 | $5.97M 10-Q · filed 2014-05-12 | $10.55M derived: sum of 2 quarters · filed 2015-03-16 | $14.33M derived: sum of 3 quarters · filed 2015-03-16 | $18.85M derived: sum of 4 quarters · filed 2015-03-16 | $47.98M 10-Q · filed 2013-05-09 | ||||||||||||
| 2012-12-31 | $4.58M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-16 | $8.35M derived: sum of 2 quarters · filed 2015-03-16 | $12.88M derived: sum of 3 quarters · filed 2015-03-16 | $17.47M 10-K · filed 2015-03-16 | $42.01M 10-K · filed 2013-03-18 | ||||||||||||
| 2012-09-30 | $3.78M 10-Q · filed 2013-11-01 | $8.30M derived: sum of 2 quarters · filed 2013-11-01 | $12.89M 10-Q · filed 2013-11-01 | $16.32M derived: sum of 4 quarters · filed 2014-03-14 | $37.42M 10-Q · filed 2012-11-14 | ||||||||||||
| 2012-06-30 | $4.53M 10-Q · filed 2013-08-05 | $9.12M 10-Q · filed 2013-08-05 | $12.55M derived: sum of 3 quarters · filed 2014-03-14 | $14.30M derived: sum of 4 quarters · filed 2014-03-14 | $33.65M 10-Q · filed 2012-08-08 | ||||||||||||
| 2012-03-31 | $4.58M 10-Q · filed 2013-05-09 | $8.02M derived: sum of 2 quarters · filed 2014-03-14 | $9.78M derived: sum of 3 quarters · filed 2014-03-14 | $11.92M derived: sum of 4 quarters · filed 2014-03-14 | $29.12M 10-Q · filed 2012-05-15 | ||||||||||||
| 2011-12-31 | $3.44M derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-14 | $5.20M derived: sum of 2 quarters · filed 2014-03-14 | $7.34M derived: sum of 3 quarters · filed 2014-03-14 | $8.58M 10-K · filed 2014-03-14 | $24.54M 10-K · filed 2012-03-29 | ||||||||||||
| 2011-09-30 | $1.75M 10-Q · filed 2012-11-14 | $3.90M derived: sum of 2 quarters · filed 2012-11-14 | $5.14M 10-Q · filed 2012-11-14 | $7.14M derived: sum of 4 quarters · filed 2013-03-18 | $21.10M 10-Q · filed 2011-11-14 | ||||||||||||
| 2011-06-30 | $2.14M 10-Q · filed 2012-08-08 | $3.39M 10-Q · filed 2012-08-08 | $5.39M derived: sum of 3 quarters · filed 2013-03-18 | $7.21M derived: sum of 4 quarters · filed 2013-03-18 | |||||||||||||
| 2011-03-31 | $1.25M 10-Q · filed 2012-05-15 | $3.25M derived: sum of 2 quarters · filed 2013-03-18 | $5.07M derived: sum of 3 quarters · filed 2013-03-18 | ||||||||||||||
| 2010-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-18 | $3.82M derived: sum of 2 quarters · filed 2013-03-18 | $8.34M 10-K · filed 2013-03-18 | ||||||||||||||
| 2010-09-30 | $1.82M 10-Q · filed 2011-11-14 | $6.34M 10-Q · filed 2011-11-14 | |||||||||||||||
| 2009-12-31 | $2.27M 10-K · filed 2012-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |